Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582400 · ClinicalTrials.gov registry record · Phase 2
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
A Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00582400: Clinical Trial Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
NCT00582400 is a Phase 2 study that was terminated before completion, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00582400, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Medical Branch, Galveston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative toxicities of this treatment, and to measure the response to treatment and the patterns of failure and survival. The primary response measurements will be the achievement of an objective tumor response, response duration and progression-free survival
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Why NCT00582400 stopped before completion
NCT00582400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00582400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00582400 about?
NCT00582400 is a clinical study titled "A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver". The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative toxicities of this treatment, and to measure the response to treatment and the...
What is the current status of trial NCT00582400?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2004-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00582400?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00582400?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00582400's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia